Jiuan Medical H1 2026 Net Profit RMB3.07 Billion, Up 233.66%; Internet Medical Revenue Up 88.19%

Jiuan Medical released its 2026 semi-annual report on the evening of August 24. The report showed that for the first half of 2026, the company achieved net profit attributable to shareholders of RMB3.07 billion, a year-on-year increase of 233.66%; net profit after deducting non-recurring gains and losses was RMB3.04 billion, up 245.17% year-on-year.

During the reporting period, revenue from internet medical products and services reached RMB94.59 million, up 88.19% year-on-year, making it the fastest-growing segment among main businesses. The diabetes diagnosis and treatment care "O+O" model has been implemented in more than 50 cities across China, with 604 partner hospitals, providing patients with full-cycle chronic disease management services. The company continues to integrate large language models, the Internet of Things, and artificial intelligence technologies into chronic disease management scenarios to optimize care service efficiency.

The iHealth series of home health monitoring products maintained stable performance in overseas markets such as North America, generating revenue of RMB338 million in the first half of the year. The company optimized its product matrix for respiratory multi-target test kits and blood pressure monitors, and iteratively upgraded home in-vitro diagnostic products. In the first half of 2026, domestic type testing and clinical trials for the continuous glucose monitoring system (CGM) proceeded in an orderly manner, while the AI-powered smart hearing aid completed prototype finalization and is about to commence trial production and product registration application.